Skip to content
ImmunovantInc

Greenlight Capital ImmunovantInc transactions over time

IMVT

ImmunovantInc historical holders

total: 2

Transactions details

Total transactions:
2
New positions:
1
Reduced:
1
Held for:
0 quarters
Latest activity:
2026 Q3
David Einhorn has been an institutional investor in ImmunovantInc (IMVT) since 2026 Q1. According to 2026 Q3 report, David Einhorn holds 70,140 shares with a market value of roughly $2.37M representing 0.07% of their equity portfolio. The fund/company first acquired IMVT in 2026 Q1, initially purchasing 93,520 shares. Since the initial investment, Greenlight Capital has made 1 more transaction in this position.

Does David Einhorn still hold IMVT?

Yes, David Einhorn continues to hold ImmunovantInc (IMVT). According to their 2026 Q3 report, they maintain a position of 70,140 shares valued at approximately $2.37M, representing 0.07% of their equity portfolio.

When did David Einhorn first invest in IMVT?

David Einhorn first invested in ImmunovantInc (IMVT) in 2026 Q1 at the reported quarter-end price of $24.84 per share, acquiring 93,520 shares in their initial purchase.

IMVT transactions history by Greenlight Capital

2 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q3
0.07%
70,140
$33.78
$2,369,329
-25.00% (-23,380)
-0.02%
2026 Q1
0.07%
93,520
$24.84
$2,323,036
new
+0.07%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.